CORRELATION OF INSULIN-LIKE GROWTH FACTOR, ITS BINDING PROTEIN AND METABOLIC PARAMETERS IN PATIENTS WITH COLORECTAL CANCER – RESULTS OF MULTIPLE REGRESSION ANALYSIS

ZVIAD MAGLAPHERIDZE; VERA KAPETIVADZE; TAMAR LAZASHVILI; IRINA KAPETIVADZE

doi:10.52340/jecm.2025.02.11

CORRELATION OF INSULIN-LIKE GROWTH FACTOR, ITS BINDING PROTEIN AND METABOLIC PARAMETERS IN PATIENTS WITH COLORECTAL CANCER – RESULTS OF MULTIPLE REGRESSION ANALYSIS

Authors

ZVIAD MAGLAPHERIDZE Tbilisi State Medical University
VERA KAPETIVADZE Tbilisi State Medical University
TAMAR LAZASHVILI Tbilisi State Medical University
IRINA KAPETIVADZE Tbilisi State Medical University

DOI:

https://doi.org/10.52340/jecm.2025.02.11

Keywords:

Colorectal Cancer, IGF-1, IGF-BP3, Insulin Resistance, Metabolic Syndrome

Abstract

The aim of the study was to study the correlation between insulin-like growth factor (IGF), its binding protein (IGF-BP3) and metabolic parameters in patients with colorectal cancer (CRC) through multiple regression analysis.

Methods. 50 patients with CRC were examined. Before the inclusion of patients in the study, the patients confirmed their willingness to participate in the study on the informed consent protocol. Blood serum of patients with malignant tumors was taken 2-3 days before surgery and determined: fasting and postprandial glucose (glucose oxidation method), fasting insulin and C-peptide (radioimmunoassay), IGF-1 and IGF-BP3 (ECLIA-assay). Insulin resistance (IR) was determined by the Homeostasis Model Assessment (HOMA) determining the HOMA-IR index. Lipid parameters were determined in the same blood samples by biochemical method. Anthropometric parameters, body mass index (BMI), systolic and diastolic blood pressure were determined for each patient. The obtained results were statistically processed through the computer program SPSS23.0. The significant factors (dependent variables) with a joint influence on the outcome were studied using the multiple linear regression model. On stage 1, IGF-1 was selected as the outcome, and on stage II – IGF-BP3.

Results. The factors with a joint influence on the value of IGF-1 were: gender, complaints - flatulence/gas/bloating and diarrhea, BMI, waist circumference, HOMA-IR, systolic blood pressure. The factors with a joint influence on the value of IGF-BP3 were: gender, complaints - flatulence/gas/bloating, HOMA-S, HOMA-IR, creatinine.

Conclusion. We should consider the gender of the patient, MS features - IR, obesity, hypertension as factors having a joint influence on the concentrations of IGF and IGF-BP3 in the patients with CRC. On the other hand, insulin sensitivity and the level of IGF-BP are negatively correlated with the development of CRC. Therefore, it is crucial to control these modifiable risk factors, primarily through lifestyle changes, which will be a major step in the prevention of CRC.

Downloads

Download data is not yet available.

References

Arcidiacono B, Iiritano S, Nocera A, Possidente K, Nevolo MT, Ventura V, Foti D, Chiefari E, Brunetti A. Insulin Resistance and Cancer Risk: An Overview of the Pathogenetic Mechanisms. Exp Diabetes Res. 2012;2012:789174.

Christopoulos PF, Msaouel P, Koutsilieris M The role of the insulin-like growth factor-1 system in breast cancer licensee BioMed Central 2015;14:43.

Esposito K, Chiodini P, Capuano A et al. Colorectal cancer association with metabolic syndrome and its components: A systematic review with meta-analysis. Endocrine. 2013;44:634–647.

Hu J, Liu X, Chi J et al. Expressions of IGF-1, ERK, GLUT4, IRS-1 in metabolic syndrome complicated with colorectal cancer and their associations with the clinical characteristics of CRC.Cancer Biomark.2018;21:883

Crawley DJ, Holmberg L et al. Serum glucose and risk of cancer: A meta-analysis. BMC Cancer. 2014;14:985.

Clemmons DR. Role of insulin-like growth factor in maintaining normal glucose homeostasis. Horm. Res. 2004;62:77–82. doi: 10.1159/000080763.

Isley WL, Underwood LE, Clemmons DR. Dietary components that regulate serum somatomedin-C concentrations in humans. J. Clin. Investig. 1983;71:175–182.

De Ita JR, Castilla-Cortázar I, Aguirre GA et al. Altered liver expression of genes involved in lipid and glucose metabolism in mice with partial IGF-1 deficiency: An experimental approach to metabolic syndrome. J. Transl. Med. 2015;13:326.

Sesti G, Sciacqua A, et al. Plasma concentration of IGF-I is independently associated with insulin sensitivity in subjects with different degrees of glucose tolerance. Diabetes Care. 2005;28:120–125.

Aguirre GA, De Ita JR, de la Garza RG, Castilla-Cortazar I. Insulin-like growth factor-1 deficiency and metabolic syndrome. J. Transl. Med. 2016;14:3.

Esposito K. Chiodini P. Capuano A et al. Colorectal cancer association with metabolic syndrome and its components: A systematic review with meta-analysis. Endocrine. 2013;44:634–647.

Hu J. Liu X. et al. Expressions of IGF-1. ERK. GLUT4. IRS-1 in metabolic syndrome complicated with colorectal cancer and their associations with the clinical characteristics of CRC. Cancer Biomark. 2018;21:883

Crawley DJ, Holmberg L. et al. Serum glucose and risk of cancer: A meta-analysis. BMC Cancer. 2014;14:985.

Yamada K, Araki S, Tamura M et al. Relation of serum total cholesterol. serum triglycerides and fasting plasma glucose to colorectal carcinoma in situ. Int. J. Epidemiol. 1998;27:794–798.

Schoen RE, Tangen CM, Kuller LH, et al. Increased blood glucose and insulin. body size. and incident colorectal cancer. J. Natl. Cancer Inst. 1999;91:1147–11454. doi: 10.1093/jnci/91.13.1147.

Chung Y.W, Han D.S, et al. Association of obesity. serum glucose and lipids with the risk of advanced colorectal adenoma and cancer: A case-control study in Korea. Dig. Liver Dis. 2006;38:668–672.

Limburg PJ, Stolzenberg-Solomon RZ, Vierkant RA et al. Insulin, Glucose, insulin resistance, and incident colorectal cancer in male smokers. Clin. Gastroenterol. Hepatol. 2006;4:1514–1521.

Gunter MJ, Hoover DR, Yu H et al. Insulin. insulin-like growth factor-I. endogenous estradiol. and risk of colorectal cancer in postmenopausal women. Cancer Res. 2008;68:329–337.

Kabat GC, Kim MY et al. A longitudinal study of serum insulin and glucose levels in relation to colorectal cancer risk among postmenopausal women. Br. J. Cancer. 2012;106:227–232.

Vulcan A, Manjer J, Ohlsson B. High blood glucose levels are associated with higher risk of colon cancer in men: A cohort study. BMC Cancer. 2017;17:842.

Xu J, Ye Y, Wu H et al. Association between markers of glucose metabolism and risk of colorectal cancer. BMJ Open. 2016;6:e011430.

Goya L, de la Puente A, Ramos S et al. Regulation of insulin-like growth factor-I and -II by glucose in primary cultures of fetal rat hepatocytes. J. Biol. Chem. 1999;274:24633–24640.

Goya L, de la Puente A, Ramos S et al. Regulation of IGF-I and -II by insulin in primary cultures of fetal rat hepatocytes. Endocrinology. 2001;142:5089–5096.

Devesa J, Almengló C, Devesa P. Multiple Effects of Growth Hormone in the Body: Is it Really the Hormone for Growth? Clin. Med. Insights Endocrinol. Diabetes. 2016;9:47–71.

Dogansen SC, Yalin GY, Tanrikulu S, Yarman S. Impact of Glucose Metabolism Disorders on IGF-1 Levels in Patients with Acromegaly. Horm. Metab. Res. 2018;50:408–413.

Tsugawa Y, Handa H, Imai T. Arginine induces IGF-1 secretion from the endoplasmic reticulum. Biochem. Biophys. Res. Commun. 2019;514:1128–1132.

Kanbur-Oksüz N, Derman O, Kinik E. Correlation of sex steroids with IGF-1 and IGFBP-3 during different pubertal stages. Turk. J. Pediatr. 2004;46:315–321.

Jogie-Brahim S, Feldman D, Oh Y. Unraveling Insulin-Like Growth Factor Binding Protein-3 Actions in Human Disease. Endocrine Reviews 2009, 30(5):417-437.

Livingstone C. Insulin-like growth factor-I (IGF-I) and clinical nutrition. Clin. Sci. 2013;125:265–280.

Chaudhari A, Gupta R, Patel S, Velingkaar N, Kondratov R. Cryptochromes regulate IGF-1 production and signaling through control of JAK2-dependent STAT5B phosphorylation. Mol. Biol. Cell. 2017;28:834–842.

Yan J, Charles JF. Gut Microbiota and IGF-1. Calcif. Tissue Int. 2018;102:406–414.